B3B

Home/B3B

About B3B

This author has not yet filled in any details.
So far B3B has created 187 blog entries.

An Unknown Billionaire’s Big Bet on Beating Aging

Forbes has a great profile feature by Matthew Herper on Osman Kibar and his company Samumed - an excerpt: "Kibar, an engineering Ph.D. who emigrated from Turkey to the U.S. for college, doesn’t need to bet on cards for money. Samumed, the San Diego firm he has been stealthily building for a decade, is the most [...]

April 13th, 2016|

Our Brain Guardians

From Salk: "By adolescence, your brain already contains most of the neurons that you’ll have for the rest of your life. But a few regions continue to grow new nerve cells—and require the services of cellular sentinels, specialized immune cells that keep the brain safe by getting rid of dead or dysfunctional cells. Now, Salk [...]

April 7th, 2016|

Human Longevity Raises More Than $220 Million

The intro of Human Longevity's press release on their raising of more than $220 million from Series A investors and pharma companies: "Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced today that the company has completed an offering of Series B Preferred Stock, raising in excess of $220 million. HLI previously raised $80 million in [...]

April 5th, 2016|

Synthesizing Bacteria with Smallest Genome Yet

Coverage/excerpts of the collaboration of researchers from Venter Institute and Synthetic Genomics, Inc. of the first minimal synthetic bacterial cell in the "race to harness life’s building blocks": First Minimal Synthetic Bacterial Cell Designed and Constructed by Scientists at Venter Institute and Synthetic Genomics, Inc. (press release) "Researchers from the J. Craig Venter Institute (JCVI) and Synthetic Genomics, [...]

March 28th, 2016|

UCSD Work Attracts Paul Allen’s Millions

Excerpt from Alex Lash's Xconomy article about Paul Allen's new $100M biotech research initiative: "Whether those headline-grabbing scenarios come true, or CRISPR-Cas9 just remains a useful tool for all kinds of biological research, one thing is for sure. CRISPR-Cas9 does what it does by cutting DNA. But in a paper published last week in Cell, [...]

March 24th, 2016|

Computing is Transforming the Life Sciences

Bradley J. Fikes has written an event recap for the San Diego Union Tribune about the recent American Chemical Society conference in San Diego, and its theme of computers in chemistry. The feature is titled, "Computing transforms chemistry, biotech - Increased processing power from Moore's Law yields new biological insights, medicines," and gets feedback from local professionals [...]

March 21st, 2016|

Orexigen Acquires All US Rights to Contrave

Terms of the Orexigen-Takeda transaction (from press release) "The transaction is expected to close in late March 2016 following receipt of clearance under the HSR Act. At the closing, Orexigen will pay Takeda $60 million to acquire Contrave U.S. rights. Following completion of the transition period, Orexigen is required to pay Takeda an additional $15 [...]

March 15th, 2016|

Event Recap: Future of Genomic Medicine Conference

San Diego Magazine has a brief event recap of the Future of Genomic Medicine Conference called "La Jolla's Geek Woodstock" - an excerpt: "Hosted by Eric Topol and the Scripps Translational Science Institute (STSI), the conference was held on March 3 and 4 at Scripps Seaside Forum and offered a quick snapshot of genomic science: successes, shortcomings, [...]

March 9th, 2016|

Epic Sciences Takes CTC Technology to the Next Level

Excerpt of podcast preview from mendelspod: "Today’s guest, Murali Prahalad, is the CEO of Epic Sciences. They are touting a new platform for analyzing circulating tumor cells, or CTCs. This has been a tricky space for companies (remember On-Q-ity?), so the big question for Murali is what makes Epic better? Murals says that previous CTC technologies made [...]

March 4th, 2016|
X